Kyorin Pharmaceutical is paying an undisclosed fee for the option to license Japanese development and marketing rights to Cyrano Therapeutics' CYR intranasal theophylline for the treatment of loss of smell, the companies said. A Phase 2 trial of the nasal spray in patients with post-viral hyposmia that was initiated in 2023 is still underway. According to the … [Read more...] about Kyorin gets option to license Cyrano’s CYR-064 intranasal theophylline for the Japanese market
Business
Ethris gets $5 million from CEPI for development of spray-dried RNA vaccines for nasal delivery
The Coalition for Epidemic Preparedness Innovations (CEPI) is providing $5 million to inhaled RNA developer Ethris for development of spray-dried RNA vaccines for nasal delivery. Ethris said that it plans to focus initially on a vaccine against influenza once a successful process is established. Within the past few months, CEPI also provided funding to an Abera … [Read more...] about Ethris gets $5 million from CEPI for development of spray-dried RNA vaccines for nasal delivery
Flu Lab invests $5 million in ENA Respiratory to support development of INNA-051 intranasal dry powder immune enhancer
According to ENA Respiratory, California-based non-profit organization Flu Lab is providing a $5 million investment to support a Phase 2 proof of concept study of the company's INNA-051 intranasal dry powder TLR2/6 agonist for the treatment of viral respiratory infections. The Phase 2 study will take place in the US and evaluate the safety and efficacy of INNA-051 for … [Read more...] about Flu Lab invests $5 million in ENA Respiratory to support development of INNA-051 intranasal dry powder immune enhancer
Start up Miist Therapeutics raises $7 million in seed money, is developing inhaled therapies for smoking cessation and migraine
California-based startup Miist Therapeutics, which calls itself "a physics-based developer of inhaled medicines," announced that it has raised $7 million in seed funding and is developing 2 candidates: MST-01 for smoking cessation and MST-02 for the treatment of migraine. Investors included Refractor Capital, Entrepreneur First, and the California Innovation Fund. … [Read more...] about Start up Miist Therapeutics raises $7 million in seed money, is developing inhaled therapies for smoking cessation and migraine
InvisiShield says it is accelerating development of its intranasal antibodies against all influenza A&B, including H5N1 bird flu
InvisiShield Technologies said that it will speed up its H5N1 / Pan-influenza intranasal antibodies development program in response to recent outbreaks of H5N1 avian flu in mammals. The company says that it can move quickly into clinical development because it previously held successful pre-IND meetings with the FDA regarding its IS101 intranasal antibody fusion … [Read more...] about InvisiShield says it is accelerating development of its intranasal antibodies against all influenza A&B, including H5N1 bird flu
Belhaven Biopharma raises $11 million for development of Nasdepi intranasal dry powder epinephrine, initiates clinical trial
North Carolina-based Belhaven Biopharma announced that it has closed a funding round that raised $11 million for continued development of the company's Nasdepi intranasal dry powder epinephrine for the treatment of anaphylaxis. The company said that the funds will support the completion of clinical development and preparations for an NDA submission. Belhaven also … [Read more...] about Belhaven Biopharma raises $11 million for development of Nasdepi intranasal dry powder epinephrine, initiates clinical trial
Vast Therapeutics gets ~$2 million NIH grant for development of ALX1 inhalation solution for the treatment of P. aeruginosa lung infections
Vast Therapeutics announced that the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) has awarded the company $1,988,594 to support a 2-year project titled "Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients." According to the company's web site, "ALX1 contains a water … [Read more...] about Vast Therapeutics gets ~$2 million NIH grant for development of ALX1 inhalation solution for the treatment of P. aeruginosa lung infections
Emergent BioSolutions acquires US and Canadian rights to Hikma’s Kloxxado naloxone nasal spray
Emergent BioSolutions announced that it has signed an agreement to acquire marketing rights to Hikma Pharmaceuticals’ Kloxxado naloxone nasal spray in the US and Canada. Kloxxado, which delivers an 8 mg dose, was approved by the FDA for the reversal of opioid overdose in September 2021. Emergent previously acquired Narcan nasal spray, which delivers a 4 mg dose of … [Read more...] about Emergent BioSolutions acquires US and Canadian rights to Hikma’s Kloxxado naloxone nasal spray
Rein Therapeutics announces name change, upcoming Phase 2 trial of LTI-03 DPI for IPF
A Texas-based company founded as Lung Therapeutics in 2013 and acquired by Aileron Therapeutics in 2023 announced that it has now changed its name to Rein Therapeutics. Lung Therapeutics spun off TFF Pharmaceuticals in 2018 to develop dry powders based on thin film freezing technology licensed from the University of Texas. Rein Therapeutics President and CEO … [Read more...] about Rein Therapeutics announces name change, upcoming Phase 2 trial of LTI-03 DPI for IPF
Leyden Labs raises $70 million for development of its intranasal vaccine platform
Intranasal vaccine developer Leyden Laboratories announced the closing of a $70 million funding round, with proceeds going to support development of prophylactic nasal sprays based on the company's "Mucosal Protection Platform." Leyden Labs, which initiated a Phase 1 trial of its lead candidate, PanFlu intranasal CR9114 anti-hemagglutinin stem human antibody, in … [Read more...] about Leyden Labs raises $70 million for development of its intranasal vaccine platform